Clinical Trial Update: Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating an HIV vaccine (gp120/NefTat/AS02A) in individuals with chronic HIV-1 infection on HAART has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• gp120/NefTat/AS02A vaccine (gp120/NefTat/AS02A)

Snippet

Sponsor: Marcus Altfeld, M.D., Ph.D. | Conditions: HIV Infections | Phase 1 | Status: COMPLETED